首页 | 本学科首页   官方微博 | 高级检索  
     


Binding Mode and Structure–Activity Relationships around Direct Inhibitors of the Nrf2–Keap1 Complex
Authors:Dr. Eric Jnoff  Dr. Claudia Albrecht  Dr. John J. Barker  Dr. Oliver Barker  Dr. Edward Beaumont  Dr. Steven Bromidge  Dr. Frederick Brookfield  Dr. Mark Brooks  Dr. Christian Bubert  Dr. Tom Ceska  Vincent Corden  Dr. Graham Dawson  Dr. Stephanie Duclos  Dr. Tara Fryatt  Dr. Christophe Genicot  Dr. Emilie Jigorel  Dr. Jason Kwong  Rosemary Maghames  Innocent Mushi  Dr. Richard Pike  Dr. Zara A. Sands  Dr. Myron A. Smith  Dr. Christopher C. Stimson  Dr. Jean‐Philippe Courade
Affiliation:1. UCB Pharma, UCB NewMedicines, Chemin du Foriest, 1420 Braine‐l'Alleud (Belgium);2. Evotec, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14?4RZ (UK);3. UCB Pharma, UCB NewMedicines, 208 Bath Road, Slough, Berkshire SL1?3WE (UK);4. CEM Microwave Technology Ltd. 2 Middle Slade, Buckingham, Buckinghamshire MK18?1WA (UK)
Abstract:An X‐ray crystal structure of Kelch‐like ECH‐associated protein (Keap1) co‐crystallised with (1S,2R)‐2‐[(1S)‐1‐[(1,3‐dioxo‐2,3‐dihydro‐1H‐isoindol‐2‐yl)methyl]‐1,2,3,4‐tetrahydroisoquinolin‐2‐carbonyl]cyclohexane‐1‐carboxylic acid (compound (S,R,S)‐ 1 a ) was obtained. This X‐ray crystal structure provides breakthrough experimental evidence for the true binding mode of the hit compound (S,R,S)‐ 1 a , as the ligand orientation was found to differ from that of the initial docking model, which was available at the start of the project. Crystallographic elucidation of this binding mode helped to focus and drive the drug design process more effectively and efficiently.
Keywords:CNS  co‐crystal structures  docking  Keap1  Nrf2  structure–  activity relationships
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号